Loading...

FITC anti-human CD45 Antibody

Pricing & Availability
Clone
HI30 (See other available formats)
Regulatory Status
RUO
Workshop
IV N816
Other Names
LCA, T200
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
Hi30
Human peripheral blood lymphocytes, monocytes and granulocytes stained with HI30 FITC
  • Hi30
    Human peripheral blood lymphocytes, monocytes and granulocytes stained with HI30 FITC
See FITC spectral data
Cat # Size Price Save
304005 25 tests ¥7,260
304006 100 tests ¥13,490
304054 100 µg ¥31,020
304038 500 tests ¥61,030
Description

CD45 is a 180-240 kD single chain type I membrane glycoprotein also known as leukocyte common antigen (LCA) and T200. It is a tyrosine phosphatase expressed on the plasma membrane of all hematopoietic cells, except erythrocytes and platelets. CD45 is a signaling molecule that regulates a variety of cellular processes including cell growth, differentiation, cell cycle, and oncogenic transformation. CD45 plays a critical role in T and B cell antigen receptor-mediated activation by dephosphorylating substrates including p56Lck, p59Fyn, and other Src family kinases. CD45 non-covalently associates with lymphocyte phosphatase-associated phosphoprotein (LPAP) on T and B lymphocytes. CD45 has been reported to bind galectin-1 and to be associated with several other cell surface antigens including CD1, CD2, CD3, and CD4.

Product Details
Technical data sheet

Product Details

Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Formulation
µg size: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
test sizes: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
µg sizes: 0.5 mg/mL
test sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The CD45 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining using the µg size, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application. For flow cytometric staining using the test sizes, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections and formalin-fixed paraffin-embedded tissue sections9, inhibition of CD45 functions4, immunofluorescence11, Western blotting3, and spatial biology (IBEX)16,17.

It was found that the HI30 clone and the 2D1 clone can cross block each other's binding.

Application References

(PubMed link indicates BioLegend citation)
  1. Knapp W, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.
  2. Kishihara K, et al. 1993. Cell 74:143.
  3. Esser M, et al. 2001. J. Virol. 75:6173. (WB)
  4. Yamada T, et al. 2002. J. Biol. Chem. 277:28830.
  5. Nagano M, et al. 2007. Blood 110:151.
  6. Jiang Q, et al. 2008. Blood 112:2858. PubMed
  7. Morozov A, et al. 2010. Clin Cancer Res. 16:5630. PubMed
  8. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
  9. Friedman T, et al. 1999. J. Immunol. 162:5256. (IHC)
  10. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. (FC) PubMed
  11. Rees LE, et al. 2003. Clin. Exp. Immunol. 134:497. (IF)
  12. Lee J, et al. 2015. J Exp Med. 212:385. PubMed
  13. Breton G, et al. 2015. J Exp Med. 212:401. PubMed
  14. Marquardt N, et al. 2015. J Immunol. 6:2467. PubMed
  15. Bushway ME, et al. 2014. Biol Reprod. 90(5): 110. (IF) PubMed
  16. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
  17. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Joly P, et al. 2017. PLoS One. 12(6):e0180568. PubMed
  2. Yuan Z, et al. 2018. Emerg Microbes Infect. 7:59. PubMed
  3. Yan Y, et al. 2018. JCI Insight. 3. PubMed
  4. Wu L, et al. 2018. Oncol Lett. 15:9507. PubMed
  5. Martínez‐López M et al. 2019. Immunity. 50(2):446-461 . PubMed
  6. Ding L et al. 2018. Cell reports. 25(11):2972-2980 . PubMed
  7. Rousset F, et al. 2018. Mol Ther Nucleic Acids. 14:351. PubMed
  8. Niu C, et al. 2017. Mol Med Rep. 16:4879. PubMed
  9. Sprouse ML, et al. 2019. Int J Mol Sci. 20:8. PubMed
  10. Vishnoi M, et al. 2019. Mol Oncol. 13(9): 1913. PubMed
  11. Xia Y, et al. 2019. Gastroenterol Res Pract. 2019:5436961. PubMed
  12. Saraiva L, et al. 2019. Cytometry B Clin Cytom. N/A. PubMed
  13. Selich A, et al. 2019. Stem Cell Reports. 13:262. PubMed
  14. Vishnoi M, et al. 2018. Cancer Res. 78:5349. PubMed
  15. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
  16. Koide M, et al. 2018. Tohoku J Exp Med. 244:15:00. PubMed
  17. Lee HJ, et al. 2017. Oncotarget. 8:113345. PubMed
  18. Tomellini E, et al. 2020. Cell Reports. 28(4):1063-1073.e5.. PubMed
  19. Schulz A, et al. 2019. Cell Rep. 29:1074. PubMed
  20. Gomzikova MO, et al. 2019. Cells. 0.440972222. PubMed
  21. Haynes BA, et al. 2019. Arterioscler Thromb Vasc Biol. 39:2168. PubMed
  22. Li Q, et al. 2019. Am J Transl Res. 10:4322. PubMed
  23. Baccelli I, et al. 2020. Cancer Cell. 36(1):84-99. PubMed
  24. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  25. Chabi S, et al. 2020. Cell Reports. 29(8):2307-2320.e6.. PubMed
  26. Evans RDR, et al. 2020. Nat Commun. 3.491666667. PubMed
  27. Wang D, et al. 2019. Cell Res. 29:832. PubMed
  28. Oeztuerk-Winder F, et al. 2012. EMBO J. 31:3431. PubMed
  29. Hsieh J, et al. 2013. Nucleic Acids Res. 41:9753. PubMed
  30. Didigu C, et al. 2014. Blood. 123:61. PubMed
  31. Zhang B, et al. 2013. PLoS One. 8:57114. PubMed
  32. Wang L, et al. 2014. Proc Natl Acad Sci U S A. 111:3146. PubMed
  33. Skrbo N, et al. 2014. PLoS One. 9:113278. PubMed
  34. Saunders L, et al. 2015. Sci Transl Med. 7: 302ra136. PubMed
  35. Grove K, et al. 2016. PLoS One. 11: 0145961. PubMed
  36. Pabst C, et al. 2016. Blood. 127: 2018-2027. PubMed
  37. Genbacev O, et al. 2016. Hum Reprod. 31: 1300 - 1314. PubMed
  38. Yuan Z, et al. 2016. J Virol. 90: 7728 - 7739. PubMed
  39. S Tzeng 2016. J Vis Exp. 118:e54582. PubMed
  40. Travaglini KJ, et al. 2020. Nature. 587:619. PubMed
  41. Garrido-Martin EM, et al. 2020. J Immunother Cancer. 8:00. PubMed
  42. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
  43. Ehlers L, et al. 2021. The FASEB Journal. 35(7):e21684. PubMed
  44. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  45. van Gastel N, et al. 2020. Cell Metabolism. 32(3):391-403.e6. PubMed
  46. Mulay A, et al. 2021. Cell Reports. 35(5):109055. PubMed
  47. Lim JT, et al. 2020. Mol Cancer Ther. 1809:19. PubMed
  48. Bailey AL, et al. 2020. bioRxiv. . PubMed
  49. Zhang S, et al. 2021. Stem Cells Int. 6616240:2021. PubMed
  50. Chen P, et al. 2021. Front Immunol. 12:689019. PubMed
  51. Okurut S, et al. 2020. Infect Immun. 88:. PubMed
  52. Labedz-Maslowska A, et al. 2020. Int J Mol Sci. 21:. PubMed
  53. Wu CL, et al. 2021. Nat Commun. 12:362. PubMed
  54. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  55. Sun YF, et al. 2021. Nat Commun. 12:4091. PubMed
  56. Jacoby E, et al. 2021. NPJ Regen Med. 6:58. PubMed
  57. Pauken CM, et al. 2021. Cancers (Basel). 13:. PubMed
  58. Zong D, et al. 2021. BMC Biol. 19:79. PubMed
  59. Beatson RE, et al. 2021. Cell Rep Med. 2:100473. PubMed
  60. Miedema A, et al. 2022. Acta Neuropathol Commun. 10:8. PubMed
  61. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  62. Zamarin D, et al. 2020. Clin Cancer Res. 26:4531. PubMed
  63. Liu Z, et al. 2021. Molecules. 26:. PubMed
  64. Sicklinger F, et al. 2021. J Clin Invest. 131:. PubMed
  65. Kerdidani D, et al. 2022. J Exp Med. 219:. PubMed
  66. Nano R, et al. 2022. STAR Protoc. 3:101354. PubMed
  67. Xu L, et al. 2022. Int J Mol Sci. 23:. PubMed
  68. Chen X, et al. 2022. Front Bioeng Biotechnol. 10:915181. PubMed
  69. Lau D, et al. 2022. Nat Commun. 13:4053. PubMed
  70. Sun Z, et al. 2022. Stem Cell Res Ther. 13:297. PubMed
  71. Sun Q, et al. 2022. Cell Death Dis. 13:724. PubMed
  72. Yan K, et al. 2022. iScience. 25:104822. PubMed
  73. Wu SZ, et al. 2020. EMBO J. 39:e104063. PubMed
  74. Ducoli L, et al. 2021. Nat Commun. 12:925. PubMed
  75. Blomme EE, et al. 2021. Clin Transl Immunology. 10:e1287. PubMed
  76. Dai Z, et al. 2022. Signal Transduct Target Ther. 7:85. PubMed
  77. He Y, et al. 2022. Cells. 11:. PubMed
  78. Ronaldson-Bouchard K, et al. 2022. Nat Biomed Eng. 6:351. PubMed
  79. Song M, et al. 2022. J Gene Med. 24:e3455. PubMed
  80. Ran Y, et al. 2022. Stem Cell Res Ther. 13:507. PubMed
  81. Hagel J, et al. 2021. J Immunol. 206:3073. PubMed
  82. Chang Y, et al. 2022. Cell Rep. 40:111128. PubMed
  83. Abe I, et al. 2022. Dev Cell. 57:2623. PubMed
  84. Fu H, et al. 2023. Regen Ther. 22:7. PubMed
  85. Tan D, et al. 2023. Front Oncol. 12:1043479. PubMed
  86. Chen X, et al. 2023. Exp Ther Med. 25:99. PubMed
  87. Calvanese V, et al. 2022. Nature. 604:534. PubMed
  88. Korsunsky I, et al. 2022. Med. 3:481. PubMed
  89. Zhu H, et al. 2022. Cell Transplant. 31:9636897221106996. PubMed
  90. González-Casimiro CM, et al. 2022. Int J Mol Sci. 23:. PubMed
  91. Zheng Y, et al. 2022. Proc Natl Acad Sci U S A. 119:e2121077119. PubMed
  92. Bowley TY, et al. 2022. Cancer Res Commun. 2:1436. PubMed
  93. Liu RX, et al. 2023. iScience. 26:106140. PubMed
  94. Li D, et al. 2023. Int J Oncol. 62:. PubMed
  95. Woodley K, et al. 2023. Nat Commun. 14:2132. PubMed
  96. Okano F, et al. 2023. Cancer Res Commun. 3:640. PubMed
  97. Ishiuchi N, et al. 2023. Stem Cell Res Ther. 14:121. PubMed
RRID
AB_314393 (BioLegend Cat. No. 304005)
AB_314394 (BioLegend Cat. No. 304006)
AB_2564154 (BioLegend Cat. No. 304054)
AB_2562050 (BioLegend Cat. No. 304038)

Antigen Details

Structure
Tyrosine phosphatases, type I transmembrane protein, 180-240 kD (multiple isoforms)
Distribution

Hematopoietic cells, not expressed in circulating erythrocytes or platelets

Function
TCR and BCR mediated activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
Hematopoietic stem and progenitors, Mesenchymal Stem Cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References
  1. Thomas M. 1989. Annu. Rev. Immunol. 7:339.
  2. Trowbridge I, et al. 1994. Annu. Rev. Immunol.12:85.
Gene ID
5788 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org
Go To Top Version: 4    Revision Date: 08/19/2015

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account